Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Transitional Cell 29Carcinoma, Non-Small-Cell Lung 29Urinary Bladder Neoplasms 26Neoplasms 22Carcinoma, Renal Cell 22Carcinoma, Merkel Cell 21Neoplasm Metastasis 18Colorectal Neoplasms 16Breast Neoplasms 16Squamous Cell Carcinoma of Head and Neck 15Ovarian Neoplasms 14Triple Negative Breast Neoplasms 11Pancreatic Neoplasms 9Melanoma 9Head and Neck Neoplasms 8Stomach Neoplasms 7Recurrence 6Carcinoma, Hepatocellular 6Ureteral Neoplasms 5Small Cell Lung Carcinoma 5Prostatic Neoplasms 5Urethral Neoplasms 4Sarcoma 4Neuroendocrine Tumors 4Leukemia, Myeloid, Acute 4Glioblastoma 4Carcinoma, Squamous Cell 4Uterine Cervical Neoplasms 3Turcot syndrome 3Skin Neoplasms 3

Interventions

Vorinostat 2pembrolizumab 1nintedanib 1dactolisib 1avelumab 1Vinorelbine 1Sunitinib 1Oxaliplatin 1Levoleucovorin 1Leucovorin 1Hydroxychloroquine 1Folfox protocol 1Fluorouracil 1Dasatinib 1DOXO-EMCH 1Cetuximab 1Bevacizumab 1BN 80927 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Malignant Solid Tumour × avelumab × Clear all
NCT02923466 2022-04-27

Ph1 Administration of VSV-IFNβ-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid Tumors

Vyriad, Inc.

Phase 1 Completed
76 enrolled
Other solid neoplasm

Malignant Solid Tumour

Data powered by HemOnc (CC BY 4.0) Colophon âš¡